Multi-dose Safety and Tolerability Study of Dose Escalation of Liposomal Amikacin for Inhalation (ArikaceTM) in Cystic Fibrosis Patients with Chronic Infections Due to Pseudomonas Aeruginosa May 5, 2022 By Jesse Bufkin
A Phase II Single Arm Study of IMC-1121B in Patients with Metastatic Renal Cell Carcinoma with Disease Progression on or Intolerance to Tyrosine Kinase Inhibitor Therapy May 5, 2022 By Jesse Bufkin
A Phase II Trial to Assess the Safety of Immunosuppression Withdrawal in Liver Transplant Recipients May 5, 2022 By Jesse Bufkin
An Open-Label, Multicenter, Follow-up Trial to Evaluate the Long-Term Safety and Efficacy of Brivaracetam Used as Adjunctive Treatment at a Flexible Dose Up to a Maximum of 150 mg/day in Subjects Aged 16 Years or Older Suffering from Epilepsy May 5, 2022 By Jesse Bufkin
A Randomized, Multicenter, Phase III Study Comparing the Combination of Pazopanib and Lapatinib versus Lapatinib Monotherapy in Patients with ErbB2 over-expressing Inflammatory Breast Cancer May 5, 2022 By Jesse Bufkin
A phase IIIb, multinational, open-label, follow-on trial to C87085 designed to assess the long-term safety of certolizumab pegol, a pegylated Fab’ fragment of a humanized anti-TNF-alpha monoclonal antibody, administered at weeks 0, 2 and 4, and then every May 5, 2022 By Jesse Bufkin
A Phase II, single-arm, open-label study of Trastuzumab-MCC-DM1 Administered Intravenously to Patients with HER2-postitive Metastatic Breast Cancer May 5, 2022 By Jesse Bufkin
A Randomized, Prospective, Double-blind, Placebo-controlled, Crossover Study to Evaluate the Safety and Efficacy of Rifaximin for the Treatment of Moderate to Severe Crohn’s Disease May 5, 2022 By Jesse Bufkin
Pharmacokinetic Properties of Antiretroviral Drugs During Pregnancy: A Multi-center Trial of the International Maternal Pediatric Adolescent AIDS Clinical Trials Group (IMPAACT) May 5, 2022 By Jesse Bufkin
